Childhood Rhabdomyosarcoma Clinical Trial
Official title:
Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children
The purpose of this study is to evaluate the efficacy and safety of radiotherapy combined with apatinib mesylate in the treatment of rhabdomyosarcoma in children.
This study is a Interventional study. The target group was 3-18 years old, and the pathological stage was group II-IV recurrence or distant metastasis. A total of 48 patients were enrolled in this study. The treatment was radiotherapy combined with apatinib. The main outcome measures were ORR, DCR , OS , quality of life and drug safety. The main safety indicators were vital signs, laboratory indicators, adverse events (AE), and severe adverse events (SAE). This study is expected to be enrolled for 6 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00674193 -
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
|
N/A | |
| Completed |
NCT01496573 -
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
|
N/A |